The Motley Fool

Can the Novacyt (NCYT) share price make a comeback?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Woman sneaker shoe and Arrow on street with copy space background
Image source: Getty Images

2021 has not been kind to the Novacyt (LSE:NCYT) share price. Despite rising from 14p at the start of 2020, all the way to 852p by the end of the year, it has since collapsed to around 350p today. While the stock price has still increased by over 50% over the past 12 months, it’s firmly below its 2020 end-of-year high. But is that about to change? Let’s take a look.

The volatile Novacyt share price

I’ve previously explored this business. But as a quick reminder, Novacyt is a medical diagnostics firm that develops and sells pathogen testing kits for the medical, biotech, and food sectors.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

When Covid-19 reared its head, the firm’s management team quickly switched its focus to creating a rapid testing kit to help track the spread of the virus. This move turned out to be an excellent decision. Novacyt became the first company to bring a Covid-19 testing kit to the market – enjoying a temporary mini-monopoly in the process. In fact, this is precisely why the NCYT share price exploded last year.

Unfortunately, this upward momentum quickly reversed. A rising tide of uncertainty started brewing among investors regarding how this business would function in a post-pandemic world. Novacyt does have an extensive portfolio of non-Covid-related products. But the level of sales doesn’t come close.

Then in April this year, the worst happened. In a single decision by the Department of Health & Social Care (DHSC), the supply contract between it and Novacyt was terminated – eliminating around half of Novacyt’s Covid-19 testing kit revenue in the process. This devastating blow to the business saw the NCYT share price crash by around 40% within 24 hours.

The Novacyt NCYT share price has is risks

New revenue on the horizon

The loss of the DHSC contract is disappointing. And while the management team is pursuing legal action to reinstate the agreement, I’m sceptical of the matter being resolved any time soon. But this ultimately may not matter.

Why? Because at the start of June, the company announced it had just launched two new Covid-19 testing kits – one of which has piqued my interest and may be able to propel the NCYT share price once again. The first is a three-gene assay test that allows the business to expand its reach into the travel market since it can be used to quickly verify fit-to-fly certificates. The second is more complex. It is the first single testing kit brought to market that can identify the Indian, South African, and Brazilian variants of Covid-19.

In 2020, Novacyt proved the power of being first, especially when it comes to products in exceptionally high demand. These latest product launches might be sufficient to recover the lost DHSC revenue by expanding its existing pool of private clients, and may even lead to new public sector supply contracts.

The bottom line

The progress made this year by the management team is encouraging. At least, I think so. And if these latest products prove to be as lucrative as the business hopes, the NCYT share price could be on the verge of making an explosive comeback.

Having said that, there remain a lot of unknowns. The good news might come to nothing and at this stage, all I can do is speculate. Therefore, Novacyt is staying on my watch list until more information is available.

For now, I'd much rather invest in this:

One FTSE “Snowball Stock” With Runaway Revenues

Looking for new share ideas?

Grab this FREE report now.

Inside, you discover one FTSE company with a runaway snowball of profits.

From 2015-2019…

  • Revenues increased 38.6%.
  • Its net income went up 19.7 times!
  • Since 2012, revenues from regular users have almost DOUBLED

The opportunity here really is astounding.

In fact, one of its own board members recently snapped up 25,000 shares using their own money...

So why sit on the side lines a minute longer?

You could have the full details on this company right now.

Grab your free report – while it’s online.

Zaven Boyrazian does not own shares in Novacyt. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.